A Phase 1, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating, Single Oral Doses of Aes-103 in Subjects With Stable Sickle Cell Disease
Latest Information Update: 06 May 2021
At a glance
- Drugs BAX 555 (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions
- Sponsors AesRx
- 21 Mar 2014 New trial record